At a glance

ClinicalIndex Comparison Record

Phase 2Active· 441 target

Drug / intervention

Difluoromethylornithine (DFMO)drug

Likely dose

Difluoromethylornithine (DFMO) 750 mg/m2from record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679144

NCT02679144Phase 2ActiveHigh Momentum

Compare CT.gov

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Giselle Sholler·interventional·Posted Feb 10, 2016·Updated Jun 12, 2026

In Brief

A Phase 2 clinical trial evaluating Difluoromethylornithine (DFMO) for Neuroblastoma. Active but no longer recruiting, targeting 441 participants across 48 sites in 2 countries.

Signals

Enrolling ahead of pace

Detailed Summary

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNeuroblastoma

CountriesCanada, United States

CollaboratorsBeat NB Cancer Foundation, Team Parker for Life

Timeline

Phase 2Active

201620172018201920202021202220232024202520262027202820292030203120322033

Enrollment StartFeb 2016

First PostedFeb 2016

TodayJul 2026

Primary CompletionFeb 2028

Study CompletionFeb 2033

First PostedFeb 10, 2016

Enrollment StartFeb 1, 2016

Primary CompletionFeb 1, 2028

Study CompletionFeb 1, 2033

TodayJul 2, 2026

Enrollment to primary: 12 yearsPosted 10.4 years agoPrimary completion in 1.6 years

Interventions

Difluoromethylornithine (DFMO)drug

Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.